BLUE MARCH: Custom Antibodies and Immunoassays to Fight Colorectal Cancer
Did you know that March was the month dedicated to the fight against colorectal cancer?
Colorectal cancer is the third most frequently diagnosed cancer, and the second leading cause of cancer deaths worldwide. It is the second most common form of cancer in women, after breast cancer, and the third most common in men, after lung and prostate cancer.
In 2020, more than 1.9 million new cases of colorectal cancer and more than 930 000 deaths due to colorectal cancer were estimated to have occurred worldwide. Large geographical variations in incidence and mortality rates were observed. By 2040 the burden of colorectal cancer will increase to 3.2 million new cases per year (an increase of 63%) and 1.6 million deaths per year (World Health Organization).
More than ever the scientific community is mobilized to offer the best solutions to all from diagnosis to efficient treatments.
Custom Antibody Production and Immunoassay for Diagnostics
Ever more precise and specific tools for early patient care!
Rabbit Polyclonal & Monoclonal Antibody
Developing polyclonal antibodies is a convenient and versatile approach for the detection of target antigens. Obtaining a quality polyclonal serum that meets all specifications requires the implementation of a specific protocol. BIOTEM offers an easy switch to high affinity and specificity monoclonal antibody generation by phage display.
Mouse & Rat Monoclonal Antibody (Hybridoma / Phage Display)
BIOTEM has developed a fully recognized know-how in the discovery, the generation and the production of murine monoclonal antibodies. In addition since 1980 and with more than 150 projects per year, the team has a well established expertise in challenging targets (membrane protein, small molecule, conserved target, etc.). Monoclonal antibody development and production is mainly based on 2 technologies: Hybridoma or Phage Display (recombinant antibodies).
Immunoassays – ELISA & LFIA Rapid Tests
BIOTEM has a platform entirely dedicated to the development and manufacturing of ELISA and Lateral Flow rapid tests. From the design and development of research prototypes to the packaging of in vitro diagnostic kits (IVD), BIOTEM can support you at all stages of your projects.
Therapeutic Antibody Discovery
Phage Display Synthetic Library (Humanized VHH)
No Results-No Fee: Payment only in case of success!
Our exclusive Quinthetic LibraryTM allows to obtain antibodies very quickly. t can be an alternative to immunizations in the case of toxic, poorly immunogenic, highly conserved targets or targets that sometimes correspond to vital functions. With a design optimized for focused diversity in specific positions (CDRs and anchoring residues), the library has already allowed the identification of a large number of candidates. With over 87% success rate, we are delighted to offer our ‘No results-No fee’ results commitment.
Antibody Engineering and Humanization
Humanized antibodies constitute the majority of today’s approved therapeutic antibodies. Humanization by CDR-grafting consists in transferring parental complementarity determining regions (CDR) into human framework (FR) regions. Parental antibody specificity and affinity are conserved thanks to the preservation of residues implicated in antigen binding.
Recombinant Antibody Production
A high-performance platform for the production of your recombinant antibodies. From small to large scale, the transient transfection system is a serum free process which offers high yield of production. Several backbones, isotype and formats available.
